Paul Capital Healthcare to Participate in Panel on Non-Traditional Forms of Financing
...otechnology Industry Organization International Convention, will be held at the Georgia World Congress Center in Atlanta.
Relevant at a time when ipos
are hard to execute and equity valuations uncertain, this panel will explore various models for obtaining capital for product development other than t...
Medical Devices Get Most Funding in Slow Stretch for VC: Mid-Year Results from Healthcare Corporate Finance News
...ces," remarked Gretchen S. Swanson, Editor of Healthcare Corporate Finance News. "In addition, the current lack of demand for venture-backed ipos
is giving investors and entrepreneurs a reason to focus on intensifying efficiency and consider alternate strategic options for accessing capital.&quo...
Biotech Company Builder Papadopoulos Says Investment in Innovation Needed to Advance Drug Pipeline at Massachusetts Biotechnology Council's Ninth Annual MASS Opportunities Investment Conference
... "Following last year's MASS Opps, the private presenting companies
announced $198 million in new venture capital fundraising. Two companies
totaling more than $107 million, and twelve alliances and
partnerships were formed including a $1 billion licensing deal," said
Biotech Finishes on a High in August, Burrill Report Says
status by the FDA, the drug is on the fast track for regulatory clearance." Biotech IPO review It was another slow month for biotech ipos
with only two companies
getting their offerings completed. WuXi PharmaTech, a China-based
pharmaceutical and biotechnology research and development ou...
Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007
...Newswire/ -- Gerresheimer AG has
been listed in the Prime Standard of the Frankfurter Stock exchange since
June 11, 2007, following one of the largest ipos
of the year, with a total
issue volume of more than 900 million euros. Gerresheimer stock will be
included in the SDAX index of Deutsche Borse, Frankf...
Biotech IPOs bring in encouraging sums
CHICAGO In last weeks column, I raised the premise that in the early years of biotech it wasnt about making money but about providing radically new solutions to health care.
Theres a thread drawn to the early years of rock n roll where it was also not about making money but about expressing ...
Wisconsin IPOs are a harbinger of growing tech economy
Madison, Wis. - For the second time this year, a tech-based company in Wisconsin has announced plans to offer its stock for sale to the public. Called an initial public offering, this kind of business activity is not only important to the companies and investors who are directly involved, but t...
Global Financial Crisis Making Biotech Business Model Unsustainable, According to Ernst & Young
...% in 2008, led by strong growth in Australia.
In Australia, public-equity funding fell to levels not seen since 2002. There were a handful of ipos
in Japan and China and strong private-equity funding growth in India.
About Ernst & Young's Global Biotechnology Center
InformexUSA 2009 Opens to Strong Attendance
...et holds promise despite the economic climate. "We've all seen the reports that say that 30% of the biopharma industry has only 6 months of cash, that ipos
are down 97% and that venture financing is down 30%," said Langer. "Beneath the surface, a close look at what is actually happening in the market reve...
TechMandA.com Marketplace Streamlines M&A Process for Technology Businesses
...access to potential buyers and sellers of technology business, with reduced effort and expense.
"In a market which has seen four technology ipos
all year, technology businesses are infinitely more likely to exit through a sale than an IPO. With our new free listing marketplace, TechMandA.com i...
Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
...3 initial public offerings (IPOs) were successfully
completed in 2007, only three were completed in the first half of 2008.
Total 2007 funding through ipos
rose to US$1.1 billion, a 54% increase over
2006. The average valuation at the time of the IPO swelled to US$405
million, a 94% increase over 2006.
TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
...Sciences team builds on the expertise,
experience, international approach and demonstrated success in more than
100 previous investments and almost 40 ipos
from our biotechnology and
pharmaceutical portfolio of companies. The team combines long-standing
international investment experience with pharmaceuti...
Biotech Avoids Fall Out From Tough Quarter for Capital Markets
reflected in the fact that the Amex Pharmaceutical Index closed the quarter
down 12% at 295.23, its lowest total since October 2004."
The prevailing tough economic environment also took its toll on biotech
IPO "hopefuls" with Biolex, Light Sciences Oncology and Archemix can...
Antibody Engineering Company F-Star Buys Back Royalty Obligations
...ience team builds on
the expertise, experience, international approach and demonstrated success
in more than 100 previous investments and more than 30 ipos
biotechnology and pharmaceutical portfolio of companies.
For more information, visit http://www.tvm-capital.com
Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
...ompanies in the life sciences sector across the full spectrum of
transactions - M&A, divestments, corporate partnering/licensing (inward and
and financings. Prior to Marquant, Joy's positions included:
Vice President, Business Development at Nabi Biopharmaceuticals; Vice